background
dna
vaccin
immunogen
limit
ineffici
deliveri
needlefre
deliveri
dna
use
co
power
biojectorh
devic
compar
deliveri
needl
syring
evalu
safeti
immunogen
method
forti
adult
year
randomli
assign
intramuscular
im
vaccin
dna
vaccin
week
biojectorh
tm
needl
syring
ns
boost
im
week
ns
particl
unit
pu
equal
number
per
assign
schedul
low
high
reciproc
titer
preexist
neutral
antibodi
result
dna
inject
given
subject
complet
followup
research
sampl
collect
ifnc
elispot
respons
rate
biojectorh
ns
deliveri
week
week
post
boost
magnitud
elispot
respons
higher
biojectorh
compar
ns
group
similar
effect
respons
rate
magnitud
observ
tcell
respons
ic
envspecif
antibodi
respons
higher
biojectorprim
subject
conclus
dna
vaccin
biojectorh
welltoler
compar
needl
inject
prime
greater
ifnc
elispot
tcell
antibodi
respons
boost
immun
plasmid
dna
promis
technolog
genebas
antigen
deliveri
mani
advantag
microbi
vector
part
simplic
particular
preexist
vector
immun
construct
manufactur
rapid
candid
dna
vaccin
extrem
stabl
safe
howev
dna
vaccin
immunogen
human
less
expect
preclin
studi
mice
monkey
basi
fulli
known
like
ineffici
transfect
particularli
plasma
nuclear
membran
host
cell
major
factor
last
year
vaccin
research
center
made
signific
effort
evalu
dna
technolog
platform
vaccin
sever
viru
diseas
includ
hiv
west
nile
viru
wnv
sar
coronaviru
filovirus
influenza
virus
number
step
taken
optim
protein
express
includ
codon
modif
alter
promot
translat
enhanc
motif
chang
plasmid
backbon
varieti
dose
explor
earli
program
decis
made
use
needlefre
biojectorh
devic
base
publish
report
biojectorh
deliveri
improv
antibodi
respons
dna
vaccin
anim
human
compar
deliveri
needl
syring
n
particular
vaccin
studi
wnv
influenza
hiv
demonstr
favor
properti
dna
immun
merit
develop
three
dose
wnv
dna
vaccin
express
prm
e
protein
induc
substanti
neutral
antibodi
respons
compar
seen
hors
known
protect
influenza
program
singl
dose
influenza
ha
dna
vaccin
prime
fourfold
increas
hai
antibodi
titer
subject
follow
singl
month
boost
unadjuv
inactiv
vaccin
compar
dose
inactiv
vaccin
concept
evalu
phase
ii
studi
use
season
influenza
vaccin
hiv
vaccin
develop
program
dna
prime
broad
durabl
cell
respons
consist
antibodi
respons
follow
boost
regimen
evalu
hvtn
phase
iib
testofconcept
studi
determin
efficaci
given
progress
dna
vaccin
advanc
clinic
trial
import
understand
deliveri
approach
may
contribut
immunogen
report
result
phase
studi
compar
biojectorh
ns
deliveri
dna
vaccin
healthi
volunt
popul
factori
design
use
evalu
effect
preexist
immun
dose
boost
addit
biojectorh
deliveri
dna
found
biojector
significantli
improv
humor
cellular
immunogen
preexist
immun
booster
dose
significantli
affect
vaccineinduc
immun
respons
protocol
trial
support
consort
checklist
avail
support
inform
see
protocol
checklist
studi
approv
nation
institut
allergi
infecti
diseas
institut
review
board
perform
accord
cfr
part
us
food
drug
administr
regul
principl
express
declar
helsinki
subject
sign
written
inform
consent
document
character
safeti
toler
immunogen
profil
dna
prime
boost
vaccin
regimen
compar
two
differ
method
intramuscular
dna
administrationneedl
syring
vs
needlefre
pressur
inject
devic
biojectorh
healthi
hivneg
subject
age
time
enrol
vrc
conduct
nation
institut
health
nih
clinic
center
bethesda
md
vaccin
research
center
vrc
nation
institut
allergi
infecti
diseas
niaid
nih
depart
health
human
servic
dhh
forti
subject
twenti
low
twenti
high
adenoviru
serotyp
antibodi
titer
screen
random
ratio
receiv
dna
vaccin
intramuscularli
im
either
needl
syring
biojectorh
ratio
receiv
booster
vaccin
dose
particl
unit
pu
random
sequenc
obtain
statistician
use
computergener
random
number
stratifi
titer
posit
neg
achiev
balanc
across
studi
group
within
stratum
titer
five
subject
assign
combin
factor
dna
administr
devic
booster
dose
complet
random
dna
administr
devic
becam
known
clinician
subject
complet
electron
enrol
studi
databas
dose
vaccin
remain
blind
except
statistician
pharmacist
safeti
data
collect
follow
vaccin
boost
complet
vaccin
administ
im
needl
syring
dna
vaccin
given
week
follow
one
inject
vaccin
week
subject
selfreport
solicit
reactogen
paramet
diari
card
follow
inject
local
reactogen
dna
inject
document
clinician
assess
photograph
day
inject
laboratori
clinic
followup
continu
week
divis
aid
tabl
use
grade
sever
unsolicit
advers
event
ae
also
code
use
medic
dictionari
regulatori
activ
meddra
prepar
summari
data
signific
chang
studi
design
trial
commenc
except
addit
longterm
contact
week
part
respons
comment
made
food
drug
administr
fda
protocol
design
studi
fulli
accru
complet
design
primari
object
relat
safeti
vaccin
regimen
secondari
object
relat
immun
respons
week
rd
dna
vaccin
week
vaccin
boost
basi
sampl
size
secondari
object
determin
neutral
antibodi
titer
week
boost
social
impact
particip
vaccin
clinic
trial
studi
vaccin
develop
vrc
niaid
nih
compos
close
circular
dna
plasmid
encod
gag
pol
nef
clade
b
env
glycoprotein
clade
clade
b
clade
c
combin
equal
proport
weight
phosphat
buffer
salin
pb
compos
recombin
nonrepl
adenovir
serotyp
vector
encod
gagpol
polyprotein
clade
b
env
glycoprotein
clade
clade
b
clade
c
combin
ratio
respect
final
formul
buffer
ffb
peptid
overlap
match
sequenc
hivspecif
antigen
express
vaccin
use
puriti
pool
accord
antigen
enva
envb
envc
gag
pol
nef
use
final
concentr
mgml
stimul
vaccineinduc
cell
vitro
frequenc
antigenvaccinespecif
cell
determin
previous
describ
cryopreserv
pbmc
stimul
overnight
peptid
pool
repres
individu
vaccin
antigen
ifnc
elispot
perform
use
commerci
kit
bd
bioscienc
read
ctl
elispot
imag
analyz
cellular
technolog
ltd
cleveland
oh
express
mean
spotform
cell
sfc
per
million
pbmc
cryopreserv
pbmc
stimul
peptid
pool
hour
brefeldin
permeabil
fix
cell
evalu
flow
cytometri
express
ifnc
andor
analyz
use
flowjo
softwar
treestar
ashland
previous
describ
standard
research
elisa
perform
delin
antibodi
respons
viral
antigen
encod
within
vaccin
endpoint
titer
antibodi
determin
use
dynex
technolog
plate
coat
prepar
purifi
recombin
hiv
protein
deriv
sequenc
vaccin
antigen
endpoint
titer
calcul
dilut
serum
concentr
gave
optic
densiti
read
background
subject
screen
via
commerci
eia
abbott
laboratori
rdna
western
blot
mayo
laboratori
genet
system
western
blot
kit
biorad
laboratori
inc
serum
neutral
antibodi
level
measur
use
singl
round
replicationdefect
envpseudovirus
engin
cell
line
express
luciferas
upon
viral
infect
method
viru
strain
previous
describ
abbott
hivab
tm
rdna
eia
kit
use
diagnost
test
reactiv
result
western
blot
analys
done
mayo
laboratori
use
gs
western
blot
biorad
laboratori
redmond
wa
amplicor
monitor
test
roch
molecular
system
indianapoli
use
hiv
rna
pcr
test
regardless
eia
result
test
time
point
exploratori
analysi
assess
vaccineinduc
seropositivityseroreact
vispr
perform
altern
peptidebas
diagnost
assay
includ
selectest
multipl
version
hiv
diagnost
test
produc
biorad
accord
manufactur
instruct
publish
method
statist
method
follow
convent
use
predecessor
studi
done
post
hoc
measur
posit
tcell
respons
defin
statist
test
minimum
magnitud
threshold
specif
elispot
posit
respons
defin
least
sfc
per
million
pbmc
nonbackground
correct
mean
least
fold
greater
mean
neg
stimul
sampl
ic
posit
respons
defin
one
pvalu
fisher
exact
test
backgroundsubtract
magnitud
exceed
prespecifi
threshold
prespecifi
threshold
base
valid
neg
sampl
allow
vari
differ
peptid
cell
valu
use
peptid
cell
threshold
env
c
gag
b
peptid
elisa
posit
respons
defin
measur
endpoint
titer
comparison
proport
arm
done
use
fisher
exact
test
pair
comparison
within
individu
done
use
wilcoxon
sign
rank
test
postdna
respons
compar
vector
boost
tabl
balanc
subject
low
high
preexist
antibodi
vaccin
schedul
achiev
subject
low
high
ab
group
includ
titer
titer
enrol
random
followup
shown
figur
particip
complet
studi
vaccin
complet
protocol
plan
clinic
followup
week
one
subject
group
high
titer
screen
random
needl
administr
dna
vaccin
pu
chose
receiv
booster
vaccin
advers
experi
requir
ind
safeti
report
close
prospect
scrutini
vaccin
site
small
skin
lesion
describ
papul
scab
commonli
observ
studi
team
clinic
evalu
dna
inject
biojectorh
biojectorh
dna
inject
less
frequent
note
p
selfreport
diari
card
complet
studi
particip
resolv
without
treatment
present
lesion
primarili
observ
day
follow
vaccin
observ
clinician
subject
ns
dna
vaccin
inject
inject
reactogen
event
met
studi
criteria
prompt
review
safeti
monitor
team
grade
fever
maximum
temperatur
within
first
day
inject
episod
erythema
indur
maximum
diamet
cm
onset
day
post
inject
durat
averag
day
overal
reactogen
dna
vaccin
biojectorh
compar
ns
inject
vaccin
pu
dose
compar
pu
dose
shown
tabl
reactogen
event
resolv
without
sequela
consist
earlier
phase
experi
studi
vaccin
vaccin
pu
dosag
compar
p
pu
dosag
pattern
moder
sever
system
reactogen
except
one
case
acut
onset
first
hour
inject
frequent
accompani
fever
evid
differ
incid
moder
sever
reactogen
preexist
antibodi
titer
low
titer
group
compar
high
titer
group
antibodi
respons
measur
research
elisa
show
similar
respons
enva
envb
envc
subtyp
subject
prime
dna
biojectorh
posit
antibodi
respons
averag
higher
median
enva
rang
week
post
boost
subject
prime
dna
ns
posit
respons
median
enva
rang
figur
signific
neutral
activ
tier
hiv
isol
induc
consist
prior
studi
increas
magnitud
hivspecif
antibodi
respons
reflect
frequenc
durat
vispr
serolog
hiv
abbot
kit
posit
one
timepoint
particip
week
hiv
pcr
remain
neg
case
tabl
week
dna
vaccin
subject
biojectorh
group
p
ns
group
vaccineinduc
reactiv
eia
two
subject
miss
data
week
administr
week
among
subject
biojectorh
group
ns
group
reactiv
eia
regard
western
blot
result
biojectorh
group
posit
indetermin
unread
ns
group
posit
indetermin
unread
test
high
frequenc
vispr
ongo
develop
vaccin
platform
ancillari
studi
done
explor
util
peptidebas
recombin
diagnost
test
kit
selectest
multipl
version
gs
hiv
dna
prime
modest
statist
signific
higher
cumul
median
elispot
respons
sum
gagpolnefhighest
env
respons
biojectorh
compar
ns
group
howev
post
boost
week
cumul
median
elispot
respons
significantli
higher
p
biojectorh
compar
ns
prime
group
frequenc
ifnc
elispot
respons
peptid
pool
week
post
boost
biojectorh
group
p
ns
group
figur
one
individu
high
preexist
background
envaspecif
elispot
respons
ns
prime
group
tcell
respons
postboost
statist
differ
frequenc
biojectorh
vs
ns
p
magnitud
one
subject
high
preexist
enva
elispot
respons
also
high
background
preexist
envaspecif
tcell
respons
ic
biojectorhprim
group
slightli
higher
magnitud
tcell
respons
ic
peptid
pool
rd
dna
immun
p
sustain
figur
tcell
respons
postboost
display
similar
pattern
elispot
respons
higher
frequenc
respond
among
biojectorhprim
subject
biojectorh
vs
ns
p
higher
magnitud
week
post
boost
p
month
boost
respons
sustain
variabl
time
point
statist
differ
two
dna
deliveri
approach
figur
lack
vectorspecif
immun
eas
manufactur
stabil
plasmid
dna
make
ideal
vaccin
platform
current
studi
help
elucid
whether
deliveri
biojectorh
factor
immunogen
elicit
dna
vaccin
compar
dna
prime
biojectorh
vs
ns
follow
boost
use
candid
hiv
vaccin
current
evalu
phase
iib
clinic
trial
found
biojectorh
deliveri
dna
make
signific
contribut
immunogen
product
addit
found
despit
high
frequenc
magnitud
immun
respons
use
peptiderecombinantbas
hiv
enzym
immunoassay
assay
oppos
beadbas
method
problem
visp
r
could
larg
avoid
histor
administr
inject
vaccin
primarili
accomplish
needl
syring
ns
mass
product
make
suppli
econom
standard
commod
virtual
health
care
set
littl
risk
steril
dispos
suppli
use
dispos
properli
although
time
acknowledg
problem
develop
countri
reus
nonsteril
needl
syring
transmiss
bloodborn
pathogen
set
risk
needlestick
injuri
proper
needl
dispos
remain
concern
needlefre
inject
system
altern
ns
inject
vaccin
biojectorh
use
studi
eject
fluid
small
orific
pressur
deliv
liquid
tabl
vaccineinduc
seropositivityseroreact
vispr
studi
week
vaccin
parenter
deposit
may
control
primarili
intramuscular
im
subcutan
intraderm
im
inject
deliv
inject
layer
skin
subcutan
tissu
propel
muscl
conic
distribut
specul
needlefre
inject
devic
may
improv
immunogen
broader
dispers
inject
ns
studi
guinea
pig
show
biojectorh
deliveri
compar
ns
increas
uptak
dna
plasmid
muscl
skin
cell
near
inject
site
vaccin
deliveri
needlefre
devic
also
report
associ
increas
local
inflamm
may
enhanc
immunogen
recruit
immunocompet
inflammatori
cell
although
basic
mechan
biojectorh
deliveri
improv
potenc
dna
vaccin
unknown
consist
increas
transfect
frequenc
greater
antigen
product
could
relat
ballist
natur
inject
due
dispers
pattern
essenti
increas
number
cell
expos
dna
molecul
compar
needl
inject
much
inject
pool
needl
track
dna
deliv
needlefre
devic
clinic
trial
powderject
tm
system
use
compress
helium
project
dna
form
dri
powder
skin
anoth
devic
gene
gun
develop
exclus
dna
deliveri
use
compress
helium
shoot
nanoparticles
gold
ball
coat
dna
skin
dna
immun
either
devic
elicit
immun
respons
compar
directli
ns
deliveri
neither
devic
current
licens
biojectorh
handheld
portabl
easi
use
fdaapprov
devic
im
deliveri
clinic
product
includ
inject
children
approach
develop
improv
dna
vaccin
transfect
effici
electropor
shown
significantli
improv
immunogen
dna
vaccin
nonhuman
primat
although
result
human
studi
date
modest
studi
biojectorh
deliveri
dna
caus
slightli
greater
reactogen
ns
deliveri
event
gener
mild
well
toler
often
unnot
subject
importantli
deliveri
dna
vaccin
needlefre
biojectorh
devic
associ
improv
antibodi
ifnc
elispot
cell
respons
post
boost
associ
subtl
differ
cell
respons
post
dna
prime
significantli
amplifi
post
boost
previous
report
data
support
continu
clinic
evalu
dna
vaccin
use
biojectorh
deliveri
suggest
transfect
effici
key
factor
improv
potenc
dna
vaccin
figur
intracellular
cytokin
product
cell
boxplot
repres
sidebysid
comparison
median
magnitud
th
th
quartil
cell
intracellular
cytokin
stain
biojectorh
blue
ns
red
prime
group
baselin
day
two
dna
inject
week
post
prime
week
post
boost
week
respons
enva
gag
peptid
pool
shown
dna
week
week
studi
inject
timepoint
note
xaxi
figur
subject
dose
level
plot
togeth
p
p
p
wilcoxon
rank
sum
test
pptx
figur
intracellular
cytokin
product
cell
improv
biojectorh
deliveri
boxplot
repres
sidebysid
comparison
median
magnitud
th
th
quartil
cell
intracellular
cytokin
stain
biojectorh
blue
ns
red
prime
group
baselin
day
two
dna
inject
week
post
prime
week
post
boost
week
respons
enva
gag
peptid
pool
shown
dna
week
week
studi
inject
timepoint
note
xaxi
figur
subject
dose
level
plot
togeth
p
p
p
wilcoxon
rank
sum
test
checklist
consort
checklist
protocol
trial
protocol
pdf
